Related Experiment Video
Updated: May 19, 2026
05:07
A Mouse Abdominal Aortic Aneurysm Model by Periadventitial Calcium Chloride and Elastase Infiltration
Published on: August 2, 2024
Advances in therapy for ANCA-associated vasculitis
1Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Current Rheumatology Reports
|August 17, 2012
Summary
Rituximab is as effective as cyclophosphamide for treating severe anti-neutrophil cytoplasmic antibody-associated vasculitis. Methotrexate and plasma exchange are also discussed for managing these autoimmune diseases.
Area of Science:
- Rheumatology
- Immunology
- Internal Medicine
Background:
- Anti-neutrophil cytoplasmic antibody-associated vasculitides (AAV) encompass conditions like granulomatosis with polyangiitis and microscopic polyangiitis.
- Cyclophosphamide therapy historically transformed AAV from fatal to chronic, relapsing-remitting diseases.
- Current strategies aim to reduce or eliminate cyclophosphamide use due to its toxicity.
Purpose of the Study:
- To review seminal studies from the past decade on AAV treatment.
- To outline the current standard of care for AAV management.
- To compare efficacy of newer treatments against established therapies.
Main Methods:
- Review of randomized clinical trials and seminal studies over the last 10 years.
- Analysis of treatment outcomes for induction and maintenance of remission in AAV.
- Evaluation of therapeutic options based on disease severity (life-threatening vs. non-life-threatening).
Main Results:
- Rituximab demonstrated non-inferiority to cyclophosphamide for inducing remission in severe AAV.
- Methotrexate may be used for non-life-threatening AAV but carries a higher relapse risk.
- Plasma exchange can be an effective adjuvant therapy for life-threatening AAV.
Conclusions:
- Rituximab offers an effective alternative to cyclophosphamide for severe AAV, allowing for reduced cyclophosphamide exposure.
- Treatment decisions for AAV should be guided by disease severity and patient-specific factors.
- Ongoing research continues to refine AAV management strategies, focusing on efficacy and safety.
Related Concept Videos
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:26Nephrotic Syndrome II : Assessment and Medical Management
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...